tions for cannabis dependence is warranted. The iden
tification of the cannabinoid receptor (CB1), which has
a central role in mediating the psychoactive effects of
marijuana, creates new opportunities for the develop
ment of agonist or antagonist therapies. The use of
medications to alleviate withdrawal symptoms will
likely prove useful in treatment efforts. Moreover , as
with nicotine and alcohol dependence, the identifica
tion of compounds that affect mood or craving may also
show efficacy for treating cannabis dependence.
Last, many marijuana abusers may avoid seeking
treatment because of ambivalence about the seriousness
of their problem. Efforts directed at this non-treatment-
seeking population could create opportunities to pro
vide services that reduce problematic marijuana use.
One such intervention, the Marijuana Check-Up, is cur
rently under investigation and has shown promise.
1. Griffiths RR, Bigelow GE, Henningfield JE: Similarities in animal
and human drug-taking behavior, in: Mello NK (ed.), Advances in
Substance Abuse: Behavioral and Biological Research. Greenwich,
CT: JAI, 1980;1-90.
2. Tanda G, Munzar P, Goldberg S: Self-administration behavior is
maintained by the psychoactive ingredient of marijuana in squirrel
monkeys. Neuroscience 2000;3(11):1073-1074.
3. Compton DR, Dewey WL, Martin BR: Cannabis dependence and
tolerance production. Advances in Alcohol & Substance Abuse 1990;
4. Stephens RS, Roffman RA: Adult marijuana dependence, in: Baer
JS, Marlatt GA, McMahon RJ (eds.), Addictive Behaviors across the
Lifespan: Prevention, Treatment, and Policy Issues. Thousand Oaks,
CA: Sage, 1994;243-273.
5. American Psychiatric Association: Diagnostic and Statistical
Manual of Mental Disorders. 4th ed. Washington, DC: American Psy
chiatric Association, 1994.
6. World Health Organization: ICD-10 Classification of Mental and
Behavioural Disorders: Clinical Descriptions and Diagnostic Guide
lines. Geneva, Switzerland: World Health Organization, 1992.
7. Anthony JC, Helzer JE: Syndromes of drug abuse and dependence,
in: Robins LN, Regier DA (eds.), Psychiatric Disorders in America.
New York: Free Press, 1991;116-154.
8. Anthony JC, Warner LA, Kessler RC: Comparative epidemiology of
dependence on tobacco, alcohol, controlled substances and inhal
ants: basic findings from the National Comorbidity Survey . Experi
mental and Clinical Psychopharmacology 1994;2:244-268.
9. Hall W, Solowij N, Lemon, J: The Health and Psychological Conse
quences of Cannabis Use. National Drug Strategy Monograph No. 25.
Canberra: Australian Government Publication Services, 1994.
10. Kandel DB, Davis M: Progression to regular marijuana involve
ment: phenomenology and risk factors of near daily use, in: Glantz M,
Pickens R (eds.), Vulnerability to Drug Abuse. W ashington, DC:
American Psychological Association, 1992;221-253.
11. Stephens RS, Roffman RA, Simpson EE: Adult marijuana users
seeking treatment. Journal of Consulting & Clinical Psychology
12. Budney AJ, Radonovich KJ, Higgins ST, W ong CJ: Adults seeking
treatment for marijuana dependence: a comparison to cocaine-
dependent treatment seekers. Experimental and Clinical Psycho-
13. Copeland J, Swift W, Rees V: Clinical profile of participants in a
brief intervention program for cannabis use disorder. Journal of Sub
stance Abuse Treatment 2001;20:45-52.
14. SAMHSA: National Admissions to Substance Abuse Treatment
Services: The Treatment Episode Data Set (TEDS) 1992-1996.
Rockville, MD: U.S. Department of Health and Human Services,
15. Torres ML, Mattik RP, Chen R, Baillie A: Clients of Treatment Ser
vice Agencies: March 1995 Census Findings
. Canberra, Australia:
Commonwealth Department of Health and Human Services, 1995.
16. Devane W A, Dysarz F A, Johnson MR, Melvin LS, Howlett AC: De
termination and characterization of a cannabinoid receptor in rat
brain. Molecular Pharmacology 1988;34:605-613.
17. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B,
Congy C, et al: SR141716A, a potent and selective antagonist of the
brain cannabinoid receptor . FEBS Letters 1994;350:240-244.
18. Aceto M, Scates S, Lowe J, Martin B: Dependence on delta-9
tetrahydrocannabinol: studies on precipitated and abrupt with-
drawal. Journal of Pharmacology and Experimental Therapeutics
19. Lichtman AH, W iley JL, LaVecchia KL, Veviaser ST, Arthur DB,
W ilson DM, et al: Effects of SR 141716A after acute or chronic
cannabinoid administration in dogs. European Journal of Pharma-
20. Haney M, Comer SD, Ward AS, Foltin RW, Fischman MW : Absti-
nence symptoms following oral THC administration to humans.
21. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW: Ab-
st inence symptoms following smoked marijuana in humans.
22. Budney AJ, Hughes JR, Moore BA, Novy PL: Marijuana absti
nence effects in marijuana smokers maintained in their home envi
ronment. Archives of General Psychiatry 2001;58:917-924.
23. Kouri EM, Pope HG: Abstinence symptoms during withdrawal
from chronic marijuana use. Experimental and Clinical Psychopharma-
24. Budney AJ, Moore BA, Vandrey R, Hughes JR: The Timecourse
and Severity of Cannabis W ithdrawal (under review). University of
25. Budney AJ, Novy P, Hughes JR: Marijuana withdrawal among
adults seeking treatment for marijuana dependence. Addiction 1999;
26. Crowley TJ, Macdonald MJ, Whitmore EA, Mikulich SK: Canna
bis dependence, withdrawal, and reinforcing effects among adoles
cents with conduct symptoms and substance use disorders. Drug and
Alcohol Dependence 1998;50:27-37.
27. Hughes JR, Higgins ST, Bickel WK: Nicotine withdrawal versus
other drug withdrawal syndromes: similarities and dissimilarities.
28. deFonseca FR, Carrera MRA, Navarro M, Koob GF, W eiss F: Acti
vation of corticotropin-releasing factor in the limbic system during
cannabinoid withdrawal. Science 1997;276:2050-2054.
32S J Clin Pharmacol 2002;42:28S-33S
BUDNEY AND MOORE